Monday, June 5, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medical Director, CPI
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Director of Nursing and Administration
Certified Clinical Research Coordinator
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Hematology/Oncology Clinical Pharmacy Specialist
The University of North Carolina Medical Center
Chapel Hill, North Carolina
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This educational activity is intended for hematologist/oncologists, urologists, radiologists, nurse practitioners, nurses, and pharmacists.
The goal of this activity is to keep physicians, nursing professionals, and pharmacists abreast of the current and emerging approaches with oral antiandrogen therapies in the management of locally advanced or metastatic prostate cancer and discuss collaborative approaches for implementation of therapy.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medical Director, CPI
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Director of Nursing and Administration
Certified Clinical Research Coordinator
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Hematology/Oncology Clinical Pharmacy Specialist
The University of North Carolina Medical Center
Chapel Hill, North Carolina
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-20-034-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 3/16/2020
Valid for credit through: 3/16/2021
processing....
ACTH = adrenocorticotropic hormone
ADT = androgen deprivation therapy
AE = adverse event
APA = apalutamide
AR = androgen receptor
ASCO = American Society of Clinical Oncology
BBB = blood-brain barrier
BCRP = breast cancer resistance protein
BP = blood pressure
C = coactivator
CHADS = Congestive heart failure, Hypertension, Age, Diabetes, previous Stroke/transient ischemic attack
CNS = central nervous system
CRPC = castration-resistant prostate cancer
CSPC = castration-sensitive prostate cancer
CYP17A1 = cytochrome P450 17A1
CYP2C8 = cytochrome P450 2C8
CYP3A4 = cytochrome P450 3A4
DARO = darolutamide
DDI = drug-drug interaction
DHEA = dehydroepiandrosterone
DOAC = direct oral anticoagulant
DVT = deep vein thrombosis
ENZA = enzalutamide
GnRH = gonadotropin-releasing hormone
GU = genitourinary
HR = hazard ratio
LFT = liver function test
M0 = non-metastatic
M1 = metastatic
mCRPC = metastatic castration-resistant prostate cancer
mMFS = median metastatic-free survival
MOA = mechanism of action
mOS = median overall survival
mPFS = median progression-free survival
mPFS2 = median progression-free survival of second-line treatment
NCCN = National Comprehensive Cancer Network
nmCRPC = non-metastatic castration-resistant prostate cancer
NR = not reached
OS = overall survival
PBO = placebo
PCP = primary care physician
PE = pulmonary embolism
P-gp = P-glycoprotein
PPI = proton pump inhibitor
T = testosterone
TRAE = treatment-related adverse event
UGT = UDP-glucuronosyltransferase
| « Return to: Prostate Cancer Clinic: Multidisciplinary Team Approach to Oral Therapies |
.gif)